Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: A clinical phase I/II study

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 6, 2013, Pages 1217-1227

  Flörcken, Anne ^a   Kopp, Joachim ^a   Van Lessen, Antje ^a   Movassaghi, Kamran ^a   Takvorian, Anna ^a   Jöhrens, Korinna ^a   Möbs, Markus ^a   Schönemann, Constanze ^a   Sawitzki, Birgit ^a   Egerer, Karl ^a   Dörken, Bernd ^a   Pezzutto, Antonio ^a   Westermann, Jörg ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Dendritic cells; Immune response; Renal cell cancer; T cell response; Tumor vaccination

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD83 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; HLA A2 ANTIGEN; HLA A23 ANTIGEN; HLA A24 ANTIGEN; HLA A25 ANTIGEN; HLA A32 ANTIGEN; HLA A68 ANTIGEN; HLA A69 ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B38 ANTIGEN; HLA B49 ANTIGEN; HLA B51 ANTIGEN; HLA B52 ANTIGEN; HLA B53 ANTIGEN; HLA B57 ANTIGEN; HLA B58 ANTIGEN; HLA B59 ANTIGEN; HLA B63 ANTIGEN; HLA B77 ANTIGEN; HLA DQ7 ANTIGEN; HLA DQ8 ANTIGEN; HLA DR ANTIGEN; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CELL LYSATE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITE; DETERIORATION; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; KIDNEY METASTASIS; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; SKIN MANIFESTATION; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR CELL;

DENDRITIC CELLS; IMMUNE RESPONSE; RENAL CELL CANCER; T CELL RESPONSE; TUMOR VACCINATION;

ADULT; AGED; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL EXTRACTS; DENDRITIC CELLS; ENDOCYTOSIS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PHOSPHOPROTEINS; TREATMENT OUTCOME;

EID: 84880676595     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24149     Document Type: Article

References (59)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380-4; PMID:11357146; http://dx.doi.org/10.1038/35077246.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi.org/10. 1038/nm1100.
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30:843-52; PMID:14680319; http://dx.doi.org/10.1016/S0094-0143(03)00056-9.
4. Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev Vaccines 2009; 8:51-66; PMID:19093773; http://dx.doi.org/10.1586/14760584.8.1.51.
5. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. Lancet Oncol 2004; 5:681-9; PMID:15522656; http://dx.doi.org/10.1016/S1470-2045(04)01610-9.
6. de Gruijl TD, van den Eertwegh AJM, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines. Cancer Immunol Immunother 2008; 57:1569-77; PMID:18523771; http://dx.doi.org/10.1007/s00262-008-0536-z.
7. Sobol RE. The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther 2006; 13:725-31; PMID:16543919; http://dx.doi.org/10.1038/sj.cgt.7700950.
8. Pardoll DM. Cancer vaccines. Nat Med 1998; 4(Suppl):525-31; PMID:9585204; http://dx.doi.org/10.1038/nm0598supp-525.
9. Westermann J, Flörcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A, et al. Allogeneic genemodified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Ther 2011; 18:354-63; PMID:21068778; http://dx.doi.org/10.1038/gt.2010. 143.
10. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137:1142-62; PMID:4573839; http://dx.doi.org/10.1084/jem.137.5.1142.
11. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588.
12. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106:271-4; PMID:11509176; http://dx.doi.org/10.1016/S0092-8674(01)00448-2.
13. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-33; PMID:16308572; http://dx.doi.org/10.1172/JCI25947.
14. Wierecky J, Müller MR, Wirths S, Halder-Oehler E, Dörfel D, Schmidt SM, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006; 66:5910-8; PMID:16740731; http://dx.doi.org/10.1158/0008-5472.CAN-05-3905.
15. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Völler MC, De Weijer K, Mulders PF, et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 2007; 30:116-22; PMID:17198090; http://dx.doi.org/10.1097/01.cji. 0000211318.22902.ec.
16. Höltl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002; 8:3369-76; PMID:12429623.
17. Märten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002; 51:637-44; PMID:12439609; http://dx.doi.org/10.1007/s00262-002-0324-0.
18. Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY, et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007; 125:257-67; PMID:17916447; http://dx.doi.org/10.1016/j.clim.2007.07.014.
19. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007; 30:749-61; PMID:17893567; http://dx.doi.org/10. 1097/CJI.0b013e3180de4ce8.
20. Barbuto JA, Ensina LF, Neves AR, Bergami-Santos P, Leite KR, Marques R, et al. Dendritic celltumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 2004; 53:1111-8; PMID:15185011; http://dx.doi.org/10.1007/ s00262-004-0551-7.
21. Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10:4699-708; PMID:15269142; http://dx.doi.org/10.1158/1078-0432.CCR-04-0347.
22. Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003; 14:483-94; PMID:12691613; http://dx.doi.org/10. 1089/104303403321467243.
23. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172:1217-24; PMID:2212951; http://dx.doi.org/10.1084/jem.172.4.1217.
24. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received highdose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-96; PMID:7884429.
25. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14:2410-1; PMID:8708739.
26. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med 1998; 338:1272-8; PMID:9562581; http://dx.doi.org/10.1056/NEJM199804303381805.
27. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-96; PMID:11773181; http://dx.doi.org/10.1200/JCO.20.1.289.
28. Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2008; 65:191-9; PMID:18055210; http://dx.doi.org/10.1016/j.critrevonc. 2007.10.002.
29. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013.
30. Draube A, Klein-González N, Mattheus S, Brillant C, Hellmich M, Engert A, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 2011; 6:e18801; PMID:21533099; http://dx.doi.org/10.1371/journal.pone.0018801.
31. Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 2005; 54:663-70; PMID:15918076; http://dx.doi.org/10.1007/s00262-004-0629-2.
32. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002; 25:500-8; PMID:12439347; http://dx.doi.org/10.1097/00002371-200211000-00006.
33. Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, et al. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol Immunother 2009; 58:1587-97; PMID:19221746; http://dx.doi.org/10.1007/s00262- 009-0668-9.
34. Ranieri E, Gigante M, Storkus WJ, Gesualdo L. Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. Clin Exp Immunol 2007; 147:395-400; PMID:17302887; http://dx.doi.org/10.1111/j.1365-2249. 2006.03305.x.
35. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993; 151:4209-20; PMID:8409397.
36. Frankenberger B, Pohla H, Noessner E, Willimsky G, Papier B, Pezzutto A, et al. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs. Clin Cancer Res 2005; 11:1733-42; PMID:15755994; http://dx.doi.org/10. 1158/1078-0432.CCR-04-1883.
37. Malyguine AM, Strobl SL, Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother 2012; 61:239-47; PMID:22080408; http://dx.doi.org/10.1007/s00262-011-1148-6.
38. Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, et al. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res 2011; 50:235-47; PMID:21717071; http://dx.doi.org/10.1007/s12026- 011-8224-z.
39. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29:330-6; PMID:21149657; http://dx.doi.org/10.1200/JCO.2010.30.7744.
40. Spranger S, Javorovic M, Bürdek M, Wilde S, Mosetter B, Tippmer S, et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 2010; 185:738-47; PMID:20511554; http://dx.doi.org/10.4049/ jimmunol.1000060.
41. Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I, et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med 2007; 5:18; PMID:17430585; http://dx.doi.org/10.1186/1479-5876-5-18.
42. Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, et al. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Hum Gene Ther 2010; 21:285-97; PMID:19788391; http://dx.doi.org/10.1089/hum.2008.192.
43. Westermann J, Kopp J, van Lessen A, Hecker AC, Baskaynak G, le Coutre P, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol 2007; 137:297-306; PMID:17408402; http://dx.doi.org/10.1111/j.1365-2141.2007.06547.x.
44. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16; PMID:10655437; http://dx.doi.org/10.1093/jnci/92.3. 205.
45. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, et al.; European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol 2007; 51:1502-10; PMID:17408850; http://dx.doi.org/10.1016/j.eururo.2007.03.035.
46. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al.; European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58:398-406; PMID:20633979; http://dx.doi.org/10.1016/j.eururo.2010.06.032.
47. Escudier B, Kataja V; ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5):v137-9; PMID:20555064; http://dx.doi.org/10.1093/annonc/mdq206.
48. Brill TH, Kübler HR, von Randenborgh H, Fend F, Pohla H, Breul J, et al. Allogeneic retrovirally transduced, IL-2-and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer-a phase I clinical trial. J Gene Med 2007; 9:547-60; PMID:17514769; http://dx.doi.org/10. 1002/jgm.1051.
49. Pohla H, Frankenberger B, Stadlbauer B, Oberneder R, Hofstetter A, Willimsky G, et al. Allogeneic vaccination for renal cell carcinoma: development and monitoring. Bone Marrow Transplant 2000; 25(Suppl 2):S83-7; PMID:10933197; http://dx.doi.org/10.1038/sj.bmt.1702362.
50. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-9; PMID:10602881; http://dx.doi.org/10.1007/s002510050595.
51. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, et al. Generation of survivinspecific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000; 60:4845-9; PMID:10987296.
52. Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LO, Rath JC, et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005; 23:884-9; PMID:15603888; http://dx.doi.org/10.1016/j.vaccine. 2004.08.007.
53. Sadovnikova E, Jopling LA, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 1998; 28:193-200; PMID:9485199; http://dx.doi.org/10.1002/(SICI)1521-4141(199801)28:013.0.CO;2-K.
54. Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002; 62:5818-27; PMID:12384544.
55. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101:2290-6; PMID:9593785; http://dx.doi.org/10.1172/JCI488.
56. van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17:2257-317; PMID:14671650; http://dx.doi.org/10. 1038/sj.leu.2403202.
57. Brochet X, Lefranc MP, Giudicelli V. IMGT/VQUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008; 36(Web Server issue):W503-8; PMID:18503082; http://dx.doi.org/10.1093/nar/gkn316.
58. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 2009; 37(Database issue):D1006-12; PMID:18978023; http://dx.doi.org/10.1093/nar/gkn838.
59. Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009; 69:599-608; PMID:19147574; http://dx.doi.org/10.1158/0008-5472.CAN-08- 2361.